Research has suggested that an anti-oestrogen medication could be used to reduce people's risk of death from lung cancer.
Published in the journal Cancer and led by the Geneva Cancer Registry, the study looked at the drug tamoxifen.
Around 6,665 women who were diagnosed with breast cancer between 1980 and 2003 were monitroed by the scientists.
Some of the women were treated with anti-oestrogen therapy and others were not but all were followed until 2007 and monitored for occurrence of and death from lung cancer.
A total of 40 women developed lung cancer but 87 per cent fewer cases of death due to the cancer were recorded in the anti-oestrogen group than in the general population.
Dr Elisabetta Rapiti from the Geneva registry commented: "Our results support the hypothesis that there is a hormonal influence on lung cancer which has been suggested by findings such as the presence of oestrogen and progesterone receptors in a substantial proportion of lung cancers.
"If prospective studies confirm our results and find that anti-oestrogen agents improve lung cancer outcomes, this could have substantial implications for clinical practice."